trichostatin A

Trichostatin is a lipid of Polyketides (PK) class. Trichostatin is associated with abnormalities such as Dentatorubral-Pallidoluysian Atrophy, PARAGANGLIOMAS 3, abnormal fragmented structure, Disintegration (morphologic abnormality) and Hyperostosis, Diffuse Idiopathic Skeletal. The involved functions are known as Acetylation, Cell Differentiation process, histone modification, Gene Silencing and Transcriptional Activation. Trichostatin often locates in CD41a, Hematopoietic System, Chromatin Structure, Blood and Endothelium. The associated genes with Trichostatin are SPI1 gene, CELL Gene, Chromatin, CXCR4 gene and DNMT1 gene. The related lipids are Butyrates, Promega, butyrate, Lipopolysaccharides and Steroids. The related experimental models are Knock-out, Mouse Model, Xenograft Model and Cancer Model.

Cross Reference

Introduction

To understand associated biological information of trichostatin A, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with trichostatin A?

trichostatin A is suspected in Infection, Morphologically altered structure, Ureteral obstruction, Photosensitization, Atherosclerosis, Hypertrophic Cardiomyopathy and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with trichostatin A

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Inflammation D007249 119 associated lipids
Hypertension D006973 115 associated lipids
Glioma D005910 112 associated lipids
Per page 10 20 50 100 | Total 139

PubChem Associated disorders and diseases

What pathways are associated with trichostatin A

Lipid pathways are not clear in current pathway databases. We organized associated pathways with trichostatin A through full-text articles, including metabolic pathways or pathways of biological mechanisms.

Related references are published most in these journals:

Pathway name Related literatures
Loading... please refresh the page if content is not showing up.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with trichostatin A?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with trichostatin A?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with trichostatin A?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with trichostatin A?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with trichostatin A?

Mouse Model

Mouse Model are used in the study 'Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer.' (Majid S et al., 2010), Mouse Model are used in the study 'Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy.' (Fang MZ et al., 2005) and Mouse Model are used in the study 'Histone deacetylase 3 mediates allergic skin inflammation by regulating expression of MCP1 protein.' (Kim Y et al., 2012).

Xenograft Model

Xenograft Model are used in the study 'Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.' (Landreville S et al., 2012), Xenograft Model are used in the study 'Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells.' (Moiseeva EP et al., 2007) and Xenograft Model are used in the study 'Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.' (Touma SE et al., 2005).

Cancer Model

Cancer Model are used in the study 'Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice.' (Sanderson L et al., 2004).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with trichostatin A

Download all related citations
Per page 10 20 50 100 | Total 3126
Authors Title Published Journal PubMed Link
Flørenes VA et al. Deacetylase inhibition in malignant melanomas: impact on cell cycle regulation and survival. 2004 Melanoma Res. pmid:15179185
Ahn MR et al. Trichostatin A, a histone deacetylase inhibitor stimulate CYP3A4 proximal promoter activity in Hepa-I cells. 2004 Arch. Pharm. Res. pmid:15180307
Vanhaecke T et al. Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. 2004 Curr. Med. Chem. pmid:15180568
Kato N et al. Regulation of Chk2 gene expression in lymphoid malignancies: involvement of epigenetic mechanisms in Hodgkin's lymphoma cell lines. 2004 Cell Death Differ. pmid:15153943
Zoumpoulidou G et al. Convergence of interferon-gamma and progesterone signaling pathways in human endometrium: role of PIASy (protein inhibitor of activated signal transducer and activator of transcription-y). 2004 Mol. Endocrinol. pmid:15155784
Wang LG et al. Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line. 2004 Oncogene pmid:15156193
Klampfer L et al. Requirement of histone deacetylase activity for signaling by STAT1. 2004 J. Biol. Chem. pmid:15123634
Fu M et al. The androgen receptor acetylation site regulates cAMP and AKT but not ERK-induced activity. 2004 J. Biol. Chem. pmid:15123687
Phan D et al. Identification of Sp2 as a transcriptional repressor of carcinoembryonic antigen-related cell adhesion molecule 1 in tumorigenesis. 2004 Cancer Res. pmid:15126343
Iezzi S et al. Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin. 2004 Dev. Cell pmid:15130492
Bort R et al. Role of hepatocyte nuclear factor 3 gamma in the expression of human CYP2C genes. 2004 Arch. Biochem. Biophys. pmid:15130783
Ishii S et al. Aberrant dynamics of histone deacetylation at the thyrotropin-releasing hormone gene in resistance to thyroid hormone. 2004 Mol. Endocrinol. pmid:15131262
Winn RA and Heasley LE Gamma-catenin expression is reduced or absent in a subset of human non-small cell lung cancers, and its re-expression inhibits cell growth. 2004 Chest pmid:15136458
Jin YH et al. Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation. 2004 J. Biol. Chem. pmid:15138260
Milutinovic S et al. DNA methyltransferase 1 knock down induces gene expression by a mechanism independent of DNA methylation and histone deacetylation. 2004 J. Biol. Chem. pmid:15087453
Chang HC et al. Involvement of histone deacetylation in ras-induced down-regulation of the metastasis suppressor RECK. 2004 Cell. Signal. pmid:15093608
Nishino N et al. Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand. 2004 Bioorg. Med. Chem. Lett. pmid:15109626
Marson CM et al. Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. 2004 Bioorg. Med. Chem. Lett. pmid:15109636
Arapshian A et al. Epigenetic CRBP downregulation appears to be an evolutionarily conserved (human and mouse) and oncogene-specific phenomenon in breast cancer. 2004 Mol. Cancer pmid:15113415
Mizukami T et al. Effects of trichostatin a, a histone deacetylase inhibitor, on mouse gonadal development in vitro. 2004 J. Reprod. Dev. pmid:15118250
Ganslmayer M et al. A quadruple therapy synergistically blocks proliferation and promotes apoptosis of hepatoma cells. 2004 Oncol. Rep. pmid:15069530
Margueron R et al. Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens. 2004 J. Mol. Endocrinol. pmid:15072561
Reifenberger J et al. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. 2004 Int. J. Cancer pmid:14961576
Lu XC et al. [Effect of inhibitors for demethylation and histone deacetylase on proliferation of cell line K562 and expression of tumor related genes]. 2004 Zhongguo Shi Yan Xue Ye Xue Za Zhi pmid:14989767
Nojima H et al. Increase in DNA methylation downregulates conceptus interferon-tau gene expression. 2004 Mol. Reprod. Dev. pmid:14991730
Chua YL et al. Microarray analysis of chromatin-immunoprecipitated DNA identifies specific regions of tobacco genes associated with acetylated histones. 2004 Plant J. pmid:14996214
Khan AN et al. An epigenetically altered tumor cell vaccine. 2004 Cancer Immunol. Immunother. pmid:14997346
Ragno R et al. 3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies. 2004 J. Med. Chem. pmid:14998325
Hwang CK et al. Transcriptional regulation of mouse mu opioid receptor gene by PU.1. 2004 J. Biol. Chem. pmid:14998994
Gray SG et al. Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. 2004 Int. J. Oncol. pmid:15010814
Koch A et al. Mitogen-activated protein kinase modulation of nuclear factor-kappaB-induced granulocyte macrophage-colony-stimulating factor release from human alveolar macrophages. 2004 Am. J. Respir. Cell Mol. Biol. pmid:12871851
Aapola U et al. Epigenetic modifications affect Dnmt3L expression. 2004 Biochem. J. pmid:15015937
Burton GR et al. Microarray analysis of differentiation-specific gene expression during 3T3-L1 adipogenesis. 2004 Gene pmid:15033539
David GL et al. MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine. 2004 Cancer Biol. Ther. pmid:15034303
Liu X et al. Nuclear factor Y regulation and promoter transactivation of human ribonucleotide reductase subunit M2 gene in a Gemcitabine resistant KB clone. 2004 Biochem. Pharmacol. pmid:15041467
Elaut G et al. Rat hepatocyte suspensions as a suitable in vitro model for studying the biotransformation of histone deacetylase inhibitors. 2004 Altern Lab Anim pmid:23577441
Mai A et al. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 2. Effect of pyrrole-C2 and/or -C4 substitutions on biological activity. 2004 J. Med. Chem. pmid:14971890
Nishikawa J et al. Upregulation of LMP1 expression by histone deacetylase inhibitors in an EBV carrying NPC cell line. 2004 Virus Genes pmid:14739656
Milhem M et al. Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A. 2004 Blood pmid:14976039
Wang DF et al. QSAR studies of PC-3 cell line inhibition activity of TSA and SAHA-like hydroxamic acids. 2004 Bioorg. Med. Chem. Lett. pmid:14741273
Agostinho M et al. Human topoisomerase IIalpha: targeting to subchromosomal sites of activity during interphase and mitosis. 2004 Mol. Biol. Cell pmid:14978217
Sakata R et al. Trichostatin A activates the osteopontin gene promoter through AP1 site. 2004 Biochem. Biophys. Res. Commun. pmid:14985105
Knobbe CB et al. Hypermethylation and transcriptional downregulation of the carboxyl-terminal modulator protein gene in glioblastomas. 2004 J. Natl. Cancer Inst. pmid:15026474
Yan C et al. A novel homologous recombination system to study 92 kDa type IV collagenase transcription demonstrates that the NF-kappaB motif drives the transition from a repressed to an activated state of gene expression. 2004 FASEB J. pmid:14715692
Zelko IN and Folz RJ Sp1 and Sp3 transcription factors mediate trichostatin A-induced and basal expression of extracellular superoxide dismutase. 2004 Free Radic. Biol. Med. pmid:15451065
Chiba T et al. Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells. 2004 Oncology pmid:15452378
Jose B et al. Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones. 2004 Bioorg. Med. Chem. Lett. pmid:15454224
Uramoto H et al. p73 competes with co-activators and recruits histone deacetylase to NF-Y in the repression of PDGF beta-receptor. 2004 J. Cell. Sci. pmid:15454570
Sarg B et al. Histone H4 hyperacetylation precludes histone H4 lysine 20 trimethylation. 2004 J. Biol. Chem. pmid:15456746
Nan X et al. Potent stimulation of gene expression by histone deacetylase inhibitors on transiently transfected DNA. 2004 Biochem. Biophys. Res. Commun. pmid:15465025
Lee HS et al. Gene expression analysis in human gastric cancer cell line treated with trichostatin A and S-adenosyl-L-homocysteine using cDNA microarray. 2004 Biol. Pharm. Bull. pmid:15467184
Sangster-Guity N et al. Molecular profiling of embryonal carcinoma cells following retinoic acid or histone deacetylase inhibitor treatment. 2004 Cancer Biol. Ther. pmid:15467438
Young JC et al. Inhibitors of histone deacetylases promote hematopoietic stem cell self-renewal. 2004 Cytotherapy pmid:16146885
Um SJ et al. In vitro antitumor potential of 4-BPRE, a butyryl aminophenyl ester of retinoic acid: role of the butyryl group. 2004 Oncol. Rep. pmid:14767528
Emmans VC et al. Regulation of cellular processes by PPARgamma ligands in neuroblastoma cells is modulated by the level of retinoblastoma protein expression. 2004 Biochem. Soc. Trans. pmid:15494029
Fan X et al. Regulation of RANKL promoter activity is associated with histone remodeling in murine bone stromal cells. 2004 J. Cell. Biochem. pmid:15389882
Astrand C et al. Trichostatin A reduces hormone-induced transcription of the MMTV promoter and has pleiotropic effects on its chromatin structure. 2004 Eur. J. Biochem. pmid:15009194
Chen YX et al. Histone acetylation regulates p21WAF1 expression in human colon cancer cell lines. 2004 World J. Gastroenterol. pmid:15309711
Heltweg B et al. Subtype selective substrates for histone deacetylases. 2004 J. Med. Chem. pmid:15456267
Alikhani-Koopaei R et al. Epigenetic regulation of 11 beta-hydroxysteroid dehydrogenase type 2 expression. 2004 J. Clin. Invest. pmid:15489962
Keen JC et al. Epigenetic regulation of protein phosphatase 2A (PP2A), lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells. 2004 Cancer Biol. Ther. pmid:15662126
Ding W [A histone deacetylase inhibitor and tumor suppressing gene p53 induction synergistically induce apoptosis of cancer cells]. 2004 Hokkaido Igaku Zasshi pmid:15675303
Yamashita Y et al. cDNA microarray analysis in hepatocyte differentiation in Huh 7 cells. 2004 Cell Transplant pmid:15690981
García I et al. Chromatin rearrangements in the prnD-prnB bidirectional promoter: dependence on transcription factors. 2004 Eukaryotic Cell pmid:14871945
Takai N et al. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. 2004 Clin. Cancer Res. pmid:14871994
Jang ER et al. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. 2004 Oncogene pmid:14676837
Thelen P et al. Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells. 2004 Int. J. Oncol. pmid:14654937
Kramps C et al. E2F and Sp1/Sp3 Synergize but are not sufficient to activate the MYCN gene in neuroblastomas. 2004 J. Biol. Chem. pmid:14645238
Cosio BG et al. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. 2004 J. Exp. Med. pmid:15337792
Iijima K et al. Granulocytic differentiation of leukemic cells with t(9;11)(p22;q23) induced by all-trans-retinoic acid. 2004 Leuk. Lymphoma pmid:15291362
Jansen MS et al. Short-chain fatty acids enhance nuclear receptor activity through mitogen-activated protein kinase activation and histone deacetylase inhibition. 2004 Proc. Natl. Acad. Sci. U.S.A. pmid:15103026
Tóth KF et al. Trichostatin A-induced histone acetylation causes decondensation of interphase chromatin. 2004 J. Cell. Sci. pmid:15292402
Myzak MC et al. A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. 2004 Cancer Res. pmid:15313918
Facchetti F et al. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. 2004 Apoptosis pmid:15314285
Roh MS et al. Mechanism of histone deacetylase inhibitor Trichostatin A induced apoptosis in human osteosarcoma cells. 2004 Apoptosis pmid:15314286
Yanaihara N et al. Reduced expression of MYO18B, a candidate tumor-suppressor gene on chromosome arm 22q, in ovarian cancer. 2004 Int. J. Cancer pmid:15305387
Gaudier E et al. Butyrate specifically modulates MUC gene expression in intestinal epithelial goblet cells deprived of glucose. 2004 Am. J. Physiol. Gastrointest. Liver Physiol. pmid:15308471
Schultz BE et al. Kinetics and comparative reactivity of human class I and class IIb histone deacetylases. 2004 Biochemistry pmid:15323567
Tao D et al. Trichostatin A extends the lifespan of Drosophila melanogaster by elevating hsp22 expression. 2004 Acta Biochim. Biophys. Sin. (Shanghai) pmid:15346199
Korkmaz CG et al. Potentiation of androgen receptor transcriptional activity by inhibition of histone deacetylation--rescue of transcriptionally compromised mutants. 2004 J. Endocrinol. pmid:15350180
Akimoto T [Potentiation of radiation-induced cell killing by histone deacetylase inhibitor]. 2004 Nippon Rinsho pmid:15283155
Joung KE et al. Antiproliferative effect of trichostatin A and HC-toxin in T47D human breast cancer cells. 2004 Arch. Pharm. Res. pmid:15283467
Kang J et al. Synergistic killing of human leukemia cells by antioxidants and trichostatin A. 2004 Cancer Chemother. Pharmacol. pmid:15248029
Jin B and Ryu DY Regulation of CYP1A2 by histone deacetylase inhibitors in mouse hepatocytes. 2004 J. Biochem. Mol. Toxicol. pmid:15252868
Li X et al. Regulation of histone acetylation and apoptosis by trichostatin in HL-60 cells. 2004 J. Huazhong Univ. Sci. Technol. Med. Sci. pmid:15791844
ChuÄ­kin IA et al. [Transcription of c-fos gene and DNA binding activity of transcription factor AP-1 increase upon differentiation of mouse F9 teratocarcinoma cells]. 2004 Tsitologiia pmid:15747838
Naruse Y et al. Circadian and light-induced transcription of clock gene Per1 depends on histone acetylation and deacetylation. 2004 Mol. Cell. Biol. pmid:15226430
Alao JP et al. Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. 2004 Clin. Cancer Res. pmid:15585645
Chen WK et al. [Effect of trichostatin A on histone acetylation level and apoptosis in HL-60 cells]. 2004 Zhongguo Shi Yan Xue Ye Xue Za Zhi pmid:15228659
Kim JH et al. Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. 2004 Int. J. Radiat. Oncol. Biol. Phys. pmid:15234053
Sakamoto S et al. Histone deacetylase activity is required to recruit RNA polymerase II to the promoters of selected interferon-stimulated early response genes. 2004 J. Biol. Chem. pmid:15194680
Ng Y et al. Expression of the human myotonic dystrophy kinase-related Cdc42-binding kinase gamma is regulated by promoter DNA methylation and Sp1 binding. 2004 J. Biol. Chem. pmid:15194684
Lu H et al. Tax relieves transcriptional repression by promoting histone deacetylase 1 release from the human T-cell leukemia virus type 1 long terminal repeat. 2004 J. Virol. pmid:15194748
Moldenhauer A et al. Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins. 2004 J. Leukoc. Biol. pmid:15197237
Min KN et al. Estrogen receptor enhances the antiproliferative effects of trichostatin A and HC-toxin in human breast cancer cells. 2004 Arch. Pharm. Res. pmid:15202563
Jia S et al. RNAi-independent heterochromatin nucleation by the stress-activated ATF/CREB family proteins. 2004 Science pmid:15218150
Sumer H et al. Effects of scaffold/matrix alteration on centromeric function and gene expression. 2004 J. Biol. Chem. pmid:15220334
Lee YJ et al. Mechanism of transcriptional repression by TEL/RUNX1 fusion protein. 2004 Mol. Cells pmid:15179033
Emionite L et al. Histone deacetylase inhibitors enhance retinoid response in human breast cancer cell lines. 2004 Nov-Dec Anticancer Res. pmid:15736447
Karasawa Y and Okisaka S Inhibition of histone deacetylation by butyrate induces morphological changes in Y79 retinoblastoma cells. 2004 Nov-Dec Jpn. J. Ophthalmol. pmid:15592778